<DOC>
	<DOCNO>NCT02659631</DOCNO>
	<brief_summary>The study evaluate safety , pharmacokinetics pharmacodynamics increase dos PF-06671008 patient advance solid tumor potential P-cadherin expression . The study expand look select dose patient P-cadherin express TNBC , CRC NSCLC .</brief_summary>
	<brief_title>PF-06671008 Dose Escalation Study Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Key Inclusion Criteria Diagnosis tumor type potential Pcadherin expression resistant standard therapy standard therapy available Performance status 0 1 Adequate bone marrow , kidney liver function Key Exclusion Criteria Known CNS disease include , limited , metastases Current history seizure disorder History active autoimmune disorder Active bacterial , fungal viral infection Major surgery , anticancer therapy , radiation therapy within 4 week study treatment Requirement systemic immune suppressive medication Grade 2 great peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>P-cadherin</keyword>
	<keyword>PF-06671008</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>TNBC</keyword>
	<keyword>CRC</keyword>
	<keyword>neoplasm</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>